Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous idiotype-KLH pulsed dendritic cells
- Development stage
- Unknown
- Lead developer
- Universitätsklinikum Carl Gustav Carus
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Autologous idiotype-KLH pulsed dendritic cells is an experimental cellular immunotherapy developed by the University Hospital Carl Gustav Carus for the treatment of multiple myeloma. The therapeutic process involves isolating a patient's own dendritic cells and pulsing them with the patient's unique tumor-derived idiotype protein, which is conjugated to the immunogenic carrier protein Keyhole Limpet Hemocyanin (KLH). When re-administered to the patient, these mature, antigen-presenting dendritic cells are intended to prime the immune system, specifically T-cells, to recognize and destroy malignant plasma cells expressing the specific idiotype. This personalized vaccine approach aims to induce a durable anti-tumor immune response in patients with early-stage (Stage I) disease to delay progression or achieve remission.
- Other names
- autologous idiotype-protein pulsed dendritic cellsIdiotype-KLH loaded dendritic cellsId-KLH pulsed DC vaccine
02
Targets
Id (Tumor-specific idiotype immunoglobulin)
Beyond the preview
Go deeper on autologous idiotype-KLH pulsed dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous idiotype-KLH pulsed dendritic cells.